Patisiran

2 trials NNeurology/Psychiatry Orphan designation

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

1 Sponsors

11 Countries

Phase III

Phase III: 2

Indications tested

Cardiac amyloidosis 2 Hereditary neuropathic amyloidosis 1

Sponsors using this IMP

Alnylam Pharmaceuticals Inc. 2

All trials

2 total

A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended

2023-508364-29-00 Phase III 8 countries Alnylam Pharmaceuticals Inc.
HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended

2023-508365-33-00 Phase III 7 countries Alnylam Pharmaceuticals Inc.

Showing 1–2 of 2 trials

← All drugs A–Z